semaglutide bladder side effects and UTI: does GLP-1 therapy increase urinary tract infection risk? Semaglutide GLP-1 for Medical Weight

Both the SURPASS program (type 2 diabetes) and SURMOUNT program (obesity) reported nausea, diarrhea, and constipation among the most frequent treatment-emergent adverse events, particularly during dose escalation phases

We show that the cardioprotective actions of GLP-1(2836) do not depend on a functional transmembrane GLP-1R but rather are mediated intracellularly through type 10 soluble adenylyl cyclase (sAC), accompanied by increased cAMP levels, protein kinase A (PKA) activation, and endothelial nitric oxide synthase (eNOS) phosphorylation

ISO/IEC 17025-Accredited Laboratory Release After lyophilization, each lot is sent to an independent ISO/IEC 17025-accredited laboratory for HPLC purity, mass spectrometry identity, and bacterial endotoxin testing

These risks are rare but serious and need medical intervention if they occur